Side-by-side comparison of AI visibility scores, market position, and capabilities
Charlotte NC global lithium and specialty chemicals (NYSE: ALB) at $5.4B 2024 revenue; Q2 2025 recovery (+112% net income) with 90% of $350M cost reduction target at $1.3B quarterly sales competing with SQM and Ganfeng for EV battery lithium supply.
Albemarle Corporation is a Charlotte, North Carolina-headquartered global specialty chemicals company — publicly traded on the New York Stock Exchange (NYSE: ALB) as an S&P 500 company — operating as one of the world's largest lithium producers for electric vehicle battery supply chains, a global leader in bromine specialty chemicals, and a provider of refining catalysts. In 2024, Albemarle reported $5.4 billion in revenue with 7,400-8,300 employees across major production facilities in Chile (La Negra lithium conversion plant), China (Meishan lithium plant), and bromine production in the US, Europe, and Asia. In Q2 2025, Albemarle reported $1.3 billion in net sales (-7% year-over-year) with $23 million in net income (+112% improvement from Q2 2024 loss) — demonstrating operating recovery from the lithium price collapse despite revenue pressure, with 90% of the $350 million cost reduction target achieved. CEO J. Kent Masters has led the company since 2020 with contract extended through March 2027. Founded in 1887 in Richmond, Virginia.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.